Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data (Q31128284)

29 June 2017

1 reference

title

Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data (English)

1 reference

29 June 2017

0 references

1 reference

Ralf Baron

1

1 reference

29 June 2017

Leopold Eberhart

2

1 reference

29 June 2017

Kai-Uwe Kern

3

1 reference

29 June 2017

Stefan Regner

4

1 reference

29 June 2017

Roman Rolke

5

1 reference

29 June 2017

Christian Simanski

6

1 reference

29 June 2017

Thomas Tölle

7

1 reference

29 June 2017

publication date

9 September 2016

1 reference

29 June 2017

1 reference

29 June 2017

volume

17

1 reference

29 June 2017

issue

5

1 reference

29 June 2017

page(s)

678-700

1 reference

Chronic diseases in the European Union: the prevalence and health cost implications of chronic pain

29 June 2017

cites work

1 reference

Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment

21 January 2018

1 reference

The societal impact of pain in the European Union: health-related quality of life and healthcare resource utilization

21 January 2018

1 reference

The impact of pain on labor force participation, absenteeism and presenteeism in the European Union.

21 January 2018

1 reference

Incidence of chronic postsurgical pain (CPSP) after general surgery

21 January 2018

1 reference

(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties

21 January 2018

1 reference

Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?

21 January 2018

1 reference

The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol

21 January 2018

1 reference

Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled pha

21 January 2018

1 reference

Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain

21 January 2018

1 reference

Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study

21 January 2018

1 reference

Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial

21 January 2018

1 reference

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial

21 January 2018

1 reference

Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study

21 January 2018

1 reference

Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.

21 January 2018

1 reference

Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain

21 January 2018

1 reference

Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.

21 January 2018

1 reference

Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial

21 January 2018

1 reference

painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain

21 January 2018

1 reference

The international CHANGE PAIN physician survey: does specialism influence the perception of pain and its treatment?

21 January 2018

1 reference

Recommendations for the pharmacological management of neuropathic pain: an overview and literature update

21 January 2018

1 reference

Points to consider on switching between superiority and non-inferiority

21 January 2018

1 reference

Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain

21 January 2018

1 reference

Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain

21 January 2018

1 reference

A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain

21 January 2018

1 reference

Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials

21 January 2018

1 reference

A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy

21 January 2018

1 reference

Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain

21 January 2018

1 reference

Systematic review of tapentadol in chronic severe pain

21 January 2018

1 reference

Impact of prolonged-release oxycodone/naloxone on outcomes affecting patients' daily functioning in comparison with extended-release tapentadol: a systematic review

21 January 2018

1 reference

Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists

21 January 2018

1 reference

Influence of tapentadol retard on functional parameters in patients with severe chronic pain--is there a benefit in daily life?

21 January 2018

1 reference

Management of severe chronic pain with tapentadol prolonged release - long-term data from pain specialists

21 January 2018

1 reference

Clinical practice data regarding tapentadol prolonged release treatment for severe chronic pain - improvement of analgesia, functional competence and quality of life in particular under tapentadol monotherapy

21 January 2018

1 reference

A flood of opioids, a rising tide of deaths

21 January 2018

1 reference

The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop

21 January 2018

1 reference

Opioids for low back pain

21 January 2018

1 reference

Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes

21 January 2018

1 reference

Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain

21 January 2018

1 reference

The Clinical Opiate Withdrawal Scale (COWS).

21 January 2018

1 reference

Nonmedical use of tapentadol immediate release by college students

21 January 2018

1 reference

Assessment of the abuse of tapentadol immediate release: the first 24 months

21 January 2018

1 reference

Comparison of the risks of shopping behavior and opioid abuse between tapentadol and oxycodone and association of shopping behavior and opioid abuse

21 January 2018

1 reference

Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/PAPR.12515

1 reference

29 June 2017

1 reference